As the global spread of COVID-19 has put 韩国's bio and medical sectors in the spotlight, representative bio-风投企业 engaged in new drug 研发 located in 松岛 International City, 仁川经济自由区 (IFEZ), are drawing attention.
The CEOs of these companies have a strong will to become the world's best, presenting new paradigms through 新药开发 and building partnerships with globally recognized top institutions, contributing greatly to making 松岛 — which is leaping forward as a global bio cluster — a home for bio ventures.
We can meet RudaCure, a young venture founded in 2018 by a 36-year-old young professor. CEO Yongho Kim emphasizes that pain is not just a symptom but a disease requiring treatment, and is at the forefront of developing treatments.
He received the '2020 韩国's Person Opening the Future Award' for his contribution to presenting a new paradigm in 韩国's 新药开发 industry and enhancing the competitiveness of the bio industry.
RudaCure, together with 盆唐CHA医院, is jointly developing a treatment for spinal diseases, combining 干细胞 regenerative technology and pain control technology.